Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
HEPA

HEPA - Hepion Pharmaceuticals Inc Stock Price, Fair Value and News

$0.04-0.01 (-20.00%)
Market Closed

Price Targets

HEPA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HEPA Price Action

Last 7 days

-33.3%

Last 30 days

-33.3%

Last 90 days

-42.9%

Trailing 12 Months

-99.6%

HEPA RSI Chart

HEPA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HEPA Valuation

Market Cap

464.8K

Price/Earnings (Trailing)

-0.05

EV/EBITDA

0.16

Price/Free Cashflow

-0.11

MarketCap/EBT

-0.05

HEPA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

HEPA Fundamentals

HEPA Earnings

Earnings (TTM)

-9.2M

Earnings Growth (Yr)

90.29%

Earnings Growth (Qtr)

54.68%

HEPA Profitability

Return on Equity

-275.79%

Return on Assets

-245.13%

Free Cashflow Yield

-871.94%

HEPA Investor Care

Shares Dilution (1Y)

8547.42%

Diluted EPS (TTM)

-10.87

About Hepion Pharmaceuticals Inc

HEPA
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
 CEO
 WEBSITEhepionpharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES25

Hepion Pharmaceuticals Inc Frequently Asked Questions

HEPA is the stock ticker symbol of Hepion Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Hepion Pharmaceuticals Inc is 464.81 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check HEPA's fair value in chart for subscribers.

The fair value guage provides a quick view whether HEPA is over valued or under valued. Whether Hepion Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Hepion Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HEPA.

In the past 10 years, Hepion Pharmaceuticals Inc has provided -0.806 (multiply by 100 for percentage) rate of return.